Adkins William's Form 4 filing
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) · filed Jan 4, 2023
- Accession no.
- 0001493152-23-000319
- Filed
- Jan 4, 2023
- Trade date
- Sep 2-Dec 29, 2022
- Filing delay
- 124 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market sales total $1.60K. It was filed 124 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Adkins WilliamCIK 0001945434 | Other: Former Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 29, 2022 | COMMON STOCK | SSaleDisposed | −995 | $1.61 | −$1,601.95 | 184,071 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2022 | Common Stock | JOtherAcquired | +138,889 | –F3 | – | 138,889 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Consists of warrants to purchase 138,889 shares of common stock held by the Adkins Trust. The Adkins Trust was a holder of the Issuer's Series A convertible preferred stock, which stock converted into commons stock upon completion of the Issuer's IPO and at which time the warrants were issued to the Series A holders in accordance with the terms of the Series A preferred stock offering.
Referenced by the price of 1 transaction in Table II.
Remarks
Previously, the Reporting Person's warrant holdings had been reported in Table I of the Reporting Person's Form 3. This Form 4 has corrected the error and moved the warrant holdings to Table II. The Reporting Person ceased being a director of SHPH in December 2022 and is no longer subject to Section 16 reporting requirements.